TY  - CONF

T1  - Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2010.28.15_suppl.7516

PY  - 2010/05/20

AU  - Johnson BE

AU  - Ryan AJ

AU  - Heymach J

AU  - Stephens C

AU  - Kennedy SJ

AU  - Langmuir PB

AU  - Herbst RS

ED  - 

DO  - DOI: 10.1200/jco.2010.28.15_suppl.7516

PB  - American Society of Clinical Oncology (ASCO)

VL  - 28

IS  - 15_suppl

SP  - 7516

EP  - 7516

Y2  - 2024/10/23

ER  -